Skip to main content

Table 8 Summary of AGV compared to BGI for glaucoma

From: Comparison of the Ahmed glaucoma valve with the Baerveldt glaucoma implant: a meta-analysis

Outcomes

No of participants (studies) follow up

Quality of the evidence (GRADE)

Relative effect (95 % CI)

Anticipated absolute effects

Risk with BGI

Risk difference with AGV (95 % CI)

IOP (short-term)

685 (6 studies) 12 months

VERY LOW1 due to inconsistency

  

The mean iop (short-term) in the intervention groups was 2.12 higher (0.72 to 3.52 higher)

IOP (long-term)

659 (7 studies) 20 to 60 months

VERY LOW2 due to inconsistency

  

The mean iop (long-term) in the intervention groups was 1.85 higher (0.43 to 3.28 higher)

Success rate (short-term)

714 (5 studies) 12 months

LOW

OR 0.97 (0.56 to 1.66)

797 per 1000

5 fewer per 1000 (from 110 fewer to 70 more)

Success rate (long-term)

835 (7 studies) 20 to 60 months

LOW

OR 0.73 (0.54 to 0.99)

684 per 1000

72 fewer per 1000 (from 2 fewer to 145 fewer)

Medication (short-term)

558 (3 studies) 12 months

LOW

  

The mean medication (short-term) in the intervention groups was 0.29 higher (0.07 to 0.5 higher)

Scale from: 0 to 5.

Medication (long-term)

659 (7 studies) 20 to 60 months

LOW

  

The mean medication (long-term) in the intervention groups was 0.42 higher (0.22 to 0.62 higher)

Scale from: 0 to 5.

Total complications

971 (8 studies) 1 to 3 years

LOW

OR 0.67 (0.5 to 0.9)

377 per 1000

89 fewer per 1000 (from 24 fewer to 145 fewer)

Servere complications

971 (8 studies) 1 to 3 years

LOW

OR 0.57 (0.36 to 0.91)

110 per 1000

44 fewer per 1000 (from 9 fewer to 67 fewer)

Reoperation for glaucoma

632 (3 studies) 3 to 5 years

LOW

OR 2.7 (1.54 to 4.74)

60 per 1000

87 more per 1000 (from 29 more to 172 more)

Hypotony

724 (6 studies) 1 to 3 years

LOW

OR 0.54 (0.26 to 1.11)

83 per 1000

37 fewer per 1000 (from 60 fewer to 8 more)

Tube complications

620 (4 studies) 1 to 3 years

VERY LOW3 due to inconsistency

OR 0.68 (0.25 to 1.87)

132 per 1000

38 fewer per 1000 (from 95 fewer to 89 more)

Hyphema

620 (4 studies) 1 to 3 years

LOW

OR 0.64 (0.36 to 1.13)

109 per 1000

36 fewer per 1000 (from 67 fewer to 12 more)

Choroidal effusion

693 (5 studies) 13 to 36 months

LOW

OR 1.1 (0.72 to 1.69)

106 per 1000

11 more per 1000 (from 30 fewer to 73 more)

  1. CI: Confidence interval; RR: Risk ratio; OR: Odds ratio
  2. GRADE Working Group grades of evidence
  3. High quality: Further research is very unlikely to change our confidence in the estimate of effect
  4. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
  5. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
  6. Very low quality: We are very uncertain about the estimate
  7. 1Significant heterogeneity was observed (P = 0.08)
  8. 2Significant heterogeneity was observed (P = 0.1)
  9. 3Significant heterogeneity identified (p = 0.08)